for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brooklyn Immunotherapeutics Inc

BTX.OQ

Latest Trade

3.08USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.06

 - 

80.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.08
Open
--
Volume
--
3M AVG Volume
11.36
Today's High
--
Today's Low
--
52 Week High
80.67
52 Week Low
3.06
Shares Out (MIL)
52.04
Market Cap (MIL)
167.58
Forward P/E
-3.58
Dividend (Yield %)
--

Next Event

Q4 2021 Brooklyn Immunotherapeutics Inc Earnings Release

Latest Developments

More

Brooklyn Immunotherapeutics - On Jan 3, 2022, Co Completed Reduction In Force Comprising Eight Employees (53% Of Workforce)

Brooklyn Immunotherapeutics Announces Filing Of Registration Statement For Proposed Secondary Offering Of Shares

Brooklyn Immunotherapeutics Posts Quarterly Loss Per Share Of $1.70

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brooklyn Immunotherapeutics Inc

Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.

Industry

Business Services

Contact Info

140 58Th Street, Building A, Suite 2100

BROOKLYN, NY

92009

United States

+1.212.5821199

https://www.buzztime.com/

Executive Leadership

Allen D. Wolff

Chairman of the Board, Chief Executive Officer

Lynn Sadowski Mason

Executive Vice President - Clinical Operations

Jay Sial

Chief Administrative Officer

Kevin A. D' Amour

Chief Scientific Officer

Sandra Gurrola

Vice President - Finance

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.020

2021(E)

-1.845
Price To Earnings (TTM)
--
Price To Sales (TTM)
142.62
Price To Book (MRQ)
12.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.14
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-614.41
Return on Equity (TTM)
-510.87

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up